美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Decoy Therapeutics Inc

1.25

+0.435053.37%

盤前：1.06-0.1900-15.20%04:46 EST

成交量：1.09億

成交額：1.43億

市值：798.03萬

市盈率：-0.03

高：1.41

開：1.35

低：1.07

收：0.8150

52周最高：52.95

52周最低：0.5148

股本：638.42萬

流通股本：634.11萬

量比：72.71

換手率：1715.96%

股息：- -

股息率：- -

每股收益(TTM):-39.1909

每股收益(LYR):-86.9214

淨資產收益率：-139.55%

總資產收益率：-69.91%

市淨率：1.88

市盈率(LYR):-0.01

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Decoy Therapeutics Inc

交易所：

NASDAQ

成立時間：

- -

員工人數：

2

公司地址：

One Broadway,14th Floor,Cambridge,Massachusetts,United States

官網：

http://www.salariuspharma.com

郵編：

02142

電話：

- -

傳真：

- -

簡介：

Decoy Therapeutics Inc.是一家於2014年2月26日在特拉華州註冊成立的生物技術公司，並且其業務主要發生在馬薩諸塞州的波士頓。該公司是一家臨床階段的生物製藥公司，專註於為癌症患者開發創新治療選擇。其產品組合包括 seclidemstat，這一主要候選藥物目前正在MD安德森癌症中心進行1/2 階段臨床研究，旨在針對骨髓增生異常綜合症 (MDS) 和慢性髓單核白血病 (CMML) 等血液系統癌症，特別是為治療選擇有限的患者開發。此外，公司還在推進SP-3164，這是一種口服小分子蛋白降解劑，目前處於新藥研究階段 (IND)。

董事

名稱

職位

Frederick E. Pierce

Director and Chief Executive Officer

William K. McVicar

Chair

Arnold C. Hanish

Director

David J. Arthur

Director

Jonathan Lieber

Director

Paul Lammers

Director

Tess Burleson

Director

股東

名稱

職位

Frederick E. Pierce

Director and Chief Executive Officer

Mark J. Rosenblum

Executive Vice President of Finance and Chief Financial Officer

Barbara Hibner

Chief Scientific Officer

Peter Marschel

Chief Business Officer

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/DCOY/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DCOY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","market":"US","secType":"STK","nameCN":"Decoy Therapeutics Inc","latestPrice":1.25,"timestamp":1768338000000,"preClose":0.815,"halted":0,"volume":108810866,"hourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.25,"latestTime":"04:46 EST","volume":8227,"amount":8589.7917779,"timestamp":1768383997633},"delay":0,"floatShares":6341106,"shares":6384200,"eps":-39.1909,"marketStatus":"盤前交易","change":0.435,"latestTime":"01-14 04:46:58 EST","open":1.35,"high":1.41,"low":1.07,"amount":142501332.4554706,"amplitude":0.417178,"askPrice":1.09,"askSize":100,"bidPrice":1.06,"bidSize":1421,"shortable":3,"etf":0,"ttmEps":-39.1909,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1768401000000},"marketStatusCode":1,"adr":0,"listingDate":1422507600000,"exchange":"NASDAQ","adjPreClose":1.25,"preHourTrading":{"tag":"盘前","latestPrice":1.06,"preClose":1.25,"latestTime":"04:46 EST","volume":8227,"amount":8589.7917779,"timestamp":1768383997633},"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.25,"latestTime":"19:59 EST","volume":1719614,"amount":1907282.5938,"timestamp":1768352390180},"volumeRatio":72.70843687745302},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DCOY\",,,,,undefined,":{"symbol":"DCOY","floatShares":6341106,"roa":"-69.91%","roe":"-139.55%","lyrEps":-86.921415,"volumeRatio":72.70843687745302,"shares":6384200,"dividePrice":0,"high":1.41,"amplitude":0.417178,"preClose":0.815,"low":1.07,"week52Low":0.5148,"pbRate":"1.88","week52High":52.95,"institutionHeld":0,"latestPrice":1.25,"committee":0.868508,"eps":-39.1909,"divideRate":0,"volume":108810866,"delay":0,"ttmEps":-39.1909,"open":1.35,"prevYearClose":0.6488,"prevWeekClose":0.8198,"prevMonthClose":0.6488,"prevQuarterClose":0.6488,"fiveDayClose":0.65,"twentyDayClose":0.78,"sixtyDayClose":4.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DCOY\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DCOY\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DCOY\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DCOY","date":"2026-01-12","current":-0.031895,"percent":0.5,"low":-1.071522,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"high":-0.982229,"avg":-1.033168,"sd":0.037524,"marketCap":5233748},"quantilePoints":[{"date":"2026-01-09","current":-0.982229,"twenty":-1.053663,"median":-1.026876,"eighty":-1.000088,"marketCap":4915816},{"date":"2026-01-12","current":-1.045754,"twenty":-1.061215,"median":-1.045754,"eighty":-1.007639,"marketCap":5233748}],"updateTime":1768377267056},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":330031056,"employeeNum":2,"address":"One Broadway,14th Floor,Cambridge,Massachusetts,United States","zipCode":"02142"},"stockCompanyDetail":{"websiteUrl":"http://www.salariuspharma.com","stockEarnings":[{"period":"1week","weight":0.9231},{"period":"1month","weight":0.6026},{"period":"3month","weight":-0.7283},{"period":"6month","weight":-0.8641},{"period":"1year","weight":-0.9773},{"period":"ytd","weight":0.9266}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0176},{"period":"3month","weight":0.043},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.1933},{"period":"ytd","weight":0.0174}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Decoy Therapeutics Inc.是一家於2014年2月26日在特拉華州註冊成立的生物技術公司，並且其業務主要發生在馬薩諸塞州的波士頓。該公司是一家臨床階段的生物製藥公司，專註於為癌症患者開發創新治療選擇。其產品組合包括 seclidemstat，這一主要候選藥物目前正在MD安德森癌症中心進行1/2 階段臨床研究，旨在針對骨髓增生異常綜合症 (MDS) 和慢性髓單核白血病 (CMML) 等血液系統癌症，特別是為治療選擇有限的患者開發。此外，公司還在推進SP-3164，這是一種口服小分子蛋白降解劑，目前處於新藥研究階段 (IND)。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.099389},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.047904},{"month":3,"riseRate":0.454545,"avgChangeRate":0.000826},{"month":4,"riseRate":0.181818,"avgChangeRate":-0.073659},{"month":5,"riseRate":0.545455,"avgChangeRate":-0.005048},{"month":6,"riseRate":0.545455,"avgChangeRate":-0.047064},{"month":7,"riseRate":0.272727,"avgChangeRate":-0.136217},{"month":8,"riseRate":0.272727,"avgChangeRate":-0.111993},{"month":9,"riseRate":0.090909,"avgChangeRate":-0.12638},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.128321},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.062226},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.07199}],"exchange":"NASDAQ","name":"Decoy Therapeutics Inc","nameEN":"Decoy Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"DCOY\",market:\"US\",,,undefined,":{"directors":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"William K. McVicar","position":"Chair"},{"name":"Arnold C. Hanish","position":"Director"},{"name":"David J. Arthur","position":"Director"},{"name":"Jonathan Lieber","position":"Director"},{"name":"Paul Lammers","position":"Director"},{"name":"Tess Burleson","position":"Director"}],"executives":[{"name":"Frederick E. Pierce","position":"Director and Chief Executive Officer"},{"name":"Mark J. Rosenblum","position":"Executive Vice President of Finance and Chief Financial Officer"},{"name":"Barbara Hibner","position":"Chief Scientific Officer"},{"name":"Peter Marschel","position":"Chief Business Officer"}]}}}